Iterum Therapeutics Announces Pricing of $17.5 Million Upsized Public OfferingGlobeNewsWire • 10/23/20
UPDATE -- Iterum Therapeutics to Present Data from Phase 3 Trials in Uncomplicated and Complicated Urinary Tract Infections at IDWeek 2020GlobeNewsWire • 10/19/20
Iterum Therapeutics to Present Data from Phase 3 Trials in Uncomplicated and Complicated Urinary Tract Infections at IDWeek 2020GlobeNewsWire • 10/19/20
Iterum Therapeutics Announces Positive Pre-NDA Meeting with FDA for Sulopenem for Treatment of Uncomplicated Urinary Tract InfectionsGlobeNewsWire • 09/30/20
Iterum Therapeutics to Present at the 22nd Annual H.C. Wainwright Global Investment ConferenceGlobeNewsWire • 09/08/20
Iterum Therapeutics Announces Expiration and Preliminary Results of Rights OfferingGlobeNewsWire • 09/01/20
Iterum Therapeutics Informs Shareholders of Record Date for Planned Rights OfferingGlobeNewsWire • 07/13/20
Iterum Therapeutics Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq RulesGlobeNewsWire • 06/30/20
Iterum Therapeutics Announces Topline Results from its Phase 3 Clinical Trial of Oral Sulopenem for the Treatment of Uncomplicated Urinary Tract InfectionsGlobeNewsWire • 06/29/20
Iterum Therapeutics plc Announces Result of Proposal 8 at Annual General MeetingGlobeNewsWire • 06/15/20
Iterum Therapeutics Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq RulesGlobeNewsWire • 06/03/20
Iterum Therapeutics Announces Topline Results for a Phase 3 Clinical Trial of Oral and IV Sulopenem in Complicated Urinary Tract InfectionGlobeNewsWire • 06/01/20
Iterum Therapeutics Announces $52 Million Private Placement with New and Existing InvestorsGlobeNewsWire • 01/17/20
Iterum Therapeutics Announces Completion of Enrollment in Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract InfectionGlobeNewsWire • 12/26/19
Iterum Therapeutics Announces Topline Results from Phase 3 Clinical Trial of Oral and IV Sulopenem for the Treatment of Complicated Intra-abdominal InfectionsGlobeNewsWire • 12/10/19
Iterum Therapeutics Announces Completion of Enrollment in Phase 3 Clinical Trial of Oral and IV Sulopenem in Complicated Urinary Tract InfectionGlobeNewsWire • 11/18/19
Iterum Therapeutics PLC (ITRM) Reports Q3 Loss, Lags Revenue EstimatesZacks Investment Research • 11/13/19
Earnings Preview: Iterum Therapeutics PLC (ITRM) Q3 Earnings Expected to DeclineZacks Investment Research • 11/06/19
Iterum Therapeutics to Present at the Cantor Fitzgerald Global Healthcare ConferenceGlobeNewsWire • 09/27/19
Iterum Therapeutics PLC (ITRM) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/14/19